AUSTIN, Texas — October 2, 2025 — Leads & Copy — Tekton Research, a leading multi-site clinical trial company, has announced the promotion of Corey A. Collins to Chief Executive Officer (CEO). Collins joined Tekton in December 2023 as Chief Financial Officer, bringing over 20 years of financial and operational leadership experience across the pharmaceutical and manufacturing sectors.
Prior to Tekton, Collins held key positions at American Expediting, Dicalite Management Group and PCI Pharma Services, where he guided financial strategies that drove long-term success. In January 2025, Collins was named President following the transition of Tekton’s Founding CEO, Kip McKenzie.
Under Collins’ leadership, Tekton has strengthened its business and operational excellence, refocused its commercial strategies, achieved technology harmonization and integration and assembled a high-performing executive team to guide Tekton’s next stage of growth. Tekton has expanded by seven research sites in 2025 alone, underscoring the company’s continued momentum and commitment to patients and partners.
Wendel D. Barr, Tekton’s Chairman of the Board of Directors, said that Collins’ leadership has already played a pivotal role in Tekton’s growth and his ability to pair financial acumen with strategic vision has positioned Tekton to build on our strong foundation and accelerate our mission in clinical research.
Christopher W. Kersey, M.D., M.B.A., Founding Managing Partner of Havencrest Capital Management, said they congratulate Corey on this well-deserved appointment to CEO and that Corey’s uncompromising focus on clinical quality is complemented by his commitment to operational rigor and his successful recruitment of the clinical trial industry’s best professionals.
Collins said that it’s an honor to step into the role of CEO and continue building on Tekton’s legacy and that he is proud of the progress we’ve made this year, and I’m even more excited about what’s ahead as we grow our footprint, invest in technology and remain focused on delivering high-quality research in CNS and Cardiometabolics.
This announcement follows Tekton’s recent expansion, which included three new sites, five new investigators and the addition of a CNS thought leader.
Media Contact: Jess Lightner Director of Marketing jessica.lightner@tektonresearch.com
Source: Tekton Research
